Pirolate is the pyrimidoquinoline. It was developed as an antiasthmatic and antiallergic agent. Pirolate does show high potency in passive cutaneous anaphylaxis in rats, both by intravenous and oral routes. It has some 84 times the potency of disodium cromoglycate. Pirolate is a leukotriene biosynthesis inhibitor.

Quazolast is an orally active mast cell stabilising agent which was in development with Rhône-Poulenc Rorer. In preclinical trials Quazolast was evaluated for efficacy against acid independent (alcohol, HCl), or dependent (aspirin, indomethacin) gastric damage in rats. Quazolasts gastroprotective profile was compared to that of ranitidine. Quazolast, in direct contrast to ranitidine, protected the rat gastric mucosa from acid-independent, but not acid-dependent gastric damage. Quazolast lacked antisecretory activity in rats; however, it did heal acetic acid induced gastric ulcers in this species. In clinical trials Quazolast was superior to placebo in protecting against nasal congestion and nasal itchiness after ragweed nasal challenge.

Nufenoxole is an orally active antidiarrhoeal agent which binds to opioid receptors in the brain and myenteric plexus of the intestine. Nufenoxole is well absorbed in rat, monkey and human after oral administration. Systemic availability of nufenoxole was 85% in monkey and 102% in man. The elimination rate was much faster in rat (t1/2 of 1.8 h) and monkey (t1/2 of 4.9 h) compared with human (t1/2 of 35.8 h). Nufenoxole possesses potent antisecretory properties, which are mediated via opioid receptors and may contribute to its antidiarrhoeal action in man.

Finrozole is a nonsteroidal competitive aromatase inhibitor that is being evaluated in Phase II trials for the treatment of lower urinary tract symptoms associated with reduced androgen/estrogen ratio in aging males associated with benign prostatic hyperplasia. But this research was discontinued in 2005. In dimethylbenzanthracene-induced rat mammary carcinoma model, Finrozole causes regression of more than 80% of the established tumors. The hormone-dependent mammary tumors are inhibited to a level seen in ovariectomised animals.

Benzobarbital (under the brand name Benzona), a barbiturate derivative developed in Russia that is used to treat convulsive forms of epilepsy, newborn hemolytic disease, and insomnia.

Bentipimine was developed as an anticholinergic agent.

Bencisteine was developed as an antitussive, mucolytic agent.

Nafoxadol is an analgesic agent.

Tazasubrate was developed as a lipid-lowering agent. Tazasubrate was found to be a reliable and highly effective hypocholesterolemic agent. However, information about the current use of this compound is not available.